What Is a CRL?
A Complete Response Letter is a formal communication from the FDA indicating it cannot approve the application in its current form. It is, in practical terms, a rejection. The CRL outlines specific deficiencies — clinical concerns, safety signals, manufacturing issues, or labeling disagreements.
CRLs are not publicly released by the FDA. The drug company chooses whether and how much to disclose. Some companies publish the full letter. Others provide only a summary.
How Stocks React to CRLs
CRLs are among the most destructive events in biotech. The average stock decline is 40–70%. Small-cap companies with a single drug can lose 80%+ of their value. Larger companies with diversified pipelines absorb CRLs better.
The severity of the CRL matters. A manufacturing issue can typically be resolved in 6–12 months. A demand for an additional clinical trial can take 2–3 years and cost hundreds of millions of dollars.
What Happens After a CRL
After receiving a CRL, a company can address the deficiencies and resubmit, request a meeting with the FDA, or abandon the program. Companies that quickly announce a clear path to resubmission often recover a portion of their losses. Companies that go silent tend to continue declining.
Some of the best biotech trades have come from buying after a CRL crash when the deficiency is clearly addressable.
How to Assess CRL Risk Before a PDUFA Date
FDA reviewer briefing documents contain preliminary analysis. Negative language around safety or manufacturing compliance increases CRL risk. Inspection histories matter — if the plant received a Form 483, manufacturing-related CRL risk rises. The success rate for resubmissions after a first CRL is roughly 60–70%, lower than the overall PDUFA approval rate.
These risk factors can be systematically evaluated and incorporated into a confidence score.
Related Articles
Evaluate approval probability before the PDUFA date.
BioCatalysts.AI’s Catalyst Confidence Score™ evaluates approval probability across efficacy, safety, regulatory, and track record factors. Wall Street intelligence. Retail pricing.
See Confidence Scores →